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Summary
Background Previous studies suggested that the prevalence of chronic respiratory disease in patients hospitalised with 
COVID-19 was lower than its prevalence in the general population. The aim of this study was to assess whether 
chronic lung disease or use of inhaled corticosteroids (ICS) affects the risk of contracting severe COVID-19.
Methods In this population cohort study, records from 1205 general practices in England that contribute to the 
QResearch database were linked to Public Health England’s database of SARS-CoV-2 testing and English hospital 
admissions, intensive care unit (ICU) admissions, and deaths for COVID-19. All patients aged 20 years and older who 
were registered with one of the 1205 general practices on Jan 24, 2020, were included in this study. With Cox 
regression, we examined the risks of COVID-19-related hospitalisation, admission to ICU, and death in relation to 
respiratory disease and use of ICS, adjusting for demographic and socioeconomic status and comorbidities associated 
with severe COVID-19.
Findings Between Jan 24 and April 30, 2020, 8 256 161 people were included in the cohort and observed, of whom 
14 479 (0·2%) were admitted to hospital with COVID-19, 1542 (<0·1%) were admitted to ICU, and 5956 (0·1%) 
died. People with some respiratory diseases were at an increased risk of hospitalisation (chronic obstructive 
pulmonary disease [COPD] hazard ratio [HR] 1·54 [95% CI 1·45–1·63], asthma 1·18 [1·13–1·24], severe asthma 
1·29 [1·22–1·37;  people on three or more current asthma medications], bronchiectasis 1·34 [1·20–1·50], 
sarcoidosis 1·36 [1·10–1·68], extrinsic allergic alveolitis 1·35 [0·82–2·21], idiopathic pulmonary fibrosis 1·59 
[1·30–1·95], other interstitial lung disease 1·66 [1·30–2·12], and lung cancer 2·24 [1·89–2·65]) and death (COPD 
1·54 [1·42–1·67], asthma 0·99 [0·91–1·07], severe asthma 1·08 [0·98–1·19], bronchiectasis 1·12 [0·94–1·33], 
sarcoidosis 1·41 [0·99–1·99), extrinsic allergic alveolitis 1·56 [0·78–3·13], idiopathic pulmonary fibrosis 1·47 
[1·12–1·92], other interstitial lung disease 2·05 [1·49–2·81], and lung cancer 1·77 [1·37–2·29]) due to COVID-19 
compared with those without these diseases. Admission to ICU was rare, but the HR for people with asthma 
was 1·08 (0·93–1·25) and severe asthma was 1·30 (1·08–1·58). In a post-hoc analysis, relative risks of severe 
COVID-19 in people with respiratory disease were similar before and after shielding was introduced on 
March 23, 2020. In another post-hoc analysis, people with two or more prescriptions for ICS in the 150 days before 
study start were at a slightly higher risk of severe COVID-19 compared with all other individuals (ie, no or one ICS 
prescription): HR 1·13 (1·03–1·23) for hospitalisation, 1·63 (1·18–2·24) for ICU admission, and 1·15 (1·01–1·31) 
for death.
Interpretation The risk of severe COVID-19 in people with asthma is relatively small. People with COPD and 
interstitial lung disease appear to have a modestly increased risk of severe disease, but their risk of death from 
COVID-19 at the height of the epidemic was mostly far lower than the ordinary risk of death from any cause. Use of 
inhaled steroids might be associated with a modestly increased risk of severe COVID-19.
Funding National Institute for Health Research Oxford Biomedical Research Centre and the Wellcome Trust.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
During the COVID-19 pandemic, attention has concen-
trated on risks from cardiometabolic disease; less 
attention has been focused on chronic respiratory 
disease, although pre-existing respiratory disease might 
be expected to worsen COVID-19 disease severity. A 
review of case series showed that the prevalence of 
chronic respiratory disease in patients hospitalised with 
COVID-19 was lower than the prevalence in the general 
population.1 A subsequent systematic review found 
mixed evidence on asthma, with some data suggesting 
hospitalisation was equally probable but that COVID-19 
would probably be more severe;2 however, the evidence 
was weak. A systematic review and meta-analysis of 
cohorts of people hospitalised with COVID-19 suggested 
that chronic obstructive pulmonary disease (COPD) was 
associated with a four-times higher risk of severe 
disease (meaning intensive care unit [ICU] admission, 
death, or other critical outcomes).3 However, although 
useful for prognostication in hospital, such cohorts 
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cannot assess true risk because most people with 
COVID-19 are not admitted to hospital and decisions 
about who is and who is not admitted to hospital or to 
ICU are in part determined by severity of comorbid 
conditions. Because only a small fraction of people with 
COVID-19 are admitted to hospitals, selecting only 
hospitalised patients for cohort entry often induces bias, 
producing incorrect estimates of the size and even 
direction of effect of risk factors for deterioration or 
death.4
Data are scarce on the associations between other lung 
diseases and COVID-19. The International Severe 
Acute Respiratory and Emerging Infection Consortium 
(ISARIC) examined the risk of death in people 
hospitalised with interstitial lung diseases. After 
propensity score matching, the hazard ratio (HR) 
was 1·60 (95% CI 1·17–2·18).5 People with a greater 
restriction of vital capacity had a somewhat higher 
mortality. There were few data on the different types of 
interstitial disease.
Inhaled corticosteroids (ICS) are commonly used 
treatments for airways disease and they might modify 
the severity of COVID-19. Studies show reduced 
coronavirus replication and cytokine production in cell 
lines treated with steroids and β-agonists.6,7 By contrast, 
there is observational evidence and evidence from 
randomised trials that ICS are associated with an 
increased risk of non-COVID-19 respiratory tract 
infections.8,9 A systematic review aimed to assess the 
association between previous treatment with ICS and 
COVID-19 severity;8 however, no studies were identified. 
Since then, the OpenSAFELY cohort10 reported some 
evidence of increased risk in patients with COPD and 
patients with asthma prescribed high-dose ICS, but 
these differences were plausibly explained by risk 
factors not recorded in the available data.10
Given the dearth of data on true risks of respiratory 
disease for severe COVID-19, we undertook a cohort 
study of a large, unselected community-based population 
to examine these issues.
Research in context
Evidence before this study
We searched MEDLINE from inception of the database to 
Nov 21, 2020, using the terms “respiratory disease”, 
“COVID-19”, and “systematic review”. One review estimated 
that 5% of all people admitted to hospital with COVID-19 had 
chronic respiratory disease and a second that 8% of people 
who progressed to ICU care or who died of COVID-19 had 
respiratory disease. Two more reviews reported that the odds 
ratio for death from COVID-19 in people hospitalised with the 
disease was between two and four. One review focusing only 
on asthma produced an uncertain estimate. One community 
cohort reported little or no increased risk of severe COVID-19 
in people with asthma, but reported a 63% increased risk of 
COVID-19 death associated with all other respiratory diseases 
combined. We also searched MEDLINE from inception of the 
database to Nov 21, 2020, using the terms “COVID-19” and 
“inhaled corticosteroids” (ICS). Two systematic reviews have 
examined the evidence on whether ICS are associated with 
COVID-19 outcomes. One review found no relevant studies. 
A second reported that in people admitted to hospital with 
severe COVID-19, use of ICS was associated with faster 
recovery and shorter duration of hospital stay, but it found no 
evidence of association with need for ICU care or death. 
A community cohort study reported evidence of lower risk of 
hospital admission with COVID-19 for users of ICS than for 
people with asthma who do not use ICS. A second community 
cohort suggested that steroids were associated with a 
modestly increased risk of death from COVID-19, but residual 
confounding could have explained the association.
Added value of this study
This study used a representative and unselected cohort to 
generate risk estimates for severe COVID-19 in people with 
chronic respiratory diseases. In doing so, collider bias could be 
avoided, which often creates distorted risk estimates when the 
population studied includes only people with moderately severe 
COVID-19—defined as admission to hospital. Unlike previous 
studies of people hospitalised with COVID-19, which suggested 
large increases in risk, this cohort provides evidence that the risk 
of severe COVID-19 in people with common airways diseases is 
only modestly raised over the risk in people without such 
diseases. Interstitial lung disease appears to increase the risk of 
severe COVID-19 by around 50%. These relative risks were similar 
before and after the shielding policy was introduced. Shielding 
supported everyone with cystic fibrosis, interstitial lung disease, 
and people with particularly severe chronic obstructive 
pulmonary disease (COPD) and asthma to remain at home and 
avoid all social contact. The study provides evidence that the use 
of ICS is not associated with a substantially increased the risk of 
severe COVID-19, but nor does it appear to be associated with 
reduced risk.
Implications of all the available evidence
Asthma appears not to be associated with a major increased risk 
of the severity of COVID-19, whereas COPD and interstitial lung 
disease are associated with a 50% increased risk of severe 
COVID-19. The apparent relative risks of severe COVID-19 arising 
from chronic respiratory disease are less than those of being male 
and of having diabetes, and are a small fraction of the ordinary 
risk of death from any cause. Advice about COVID-19 to people 
with chronic respiratory disease might have inadvertently 
generated undue anxiety. Placing these modestly increased risks 
in the context of other COVID-19 risk factors and the normal risk 
of mortality might reduce anxiety reported by individuals with 
respiratory diseases. Whether using inhaled steroids is associated 
with an increased risk of severe COVID-19 remains unclear.
Articles
www.thelancet.com/respiratory   Published online April 1, 2021   https://doi.org/10.1016/S2213-2600(21)00095-3 3
Method 
Study design and participants
All adults registered with 1205 general practices in 
England contributing to the QResearch database 
(version 44, uploaded March 23, 2020) were included in 
this population cohort study. The protocol was published 
and described data and analyses on smoking that will be 
presented elsewhere.11 The data included all general 
practitioner consultations; illnesses, including those 
diagnosed in hospital that the general practitioner 
recorded; and prescriptions in primary care. These were 
linked to SARS-CoV-2 RT-PCR test records held by Public 
Health England. The QResearch records were linked to 
Hospital Episode Statistics, which gave the diagnoses of 
people admitted to hospitals in England, and the 
Intensive Care National Audit and Research Centre 
(ICNARC) Case Mix Programme database. This provided 
data from all ICUs in England. We also linked the 
QResearch database to death certificates provided by the 
Office for National Statistics.




HR (95% CI) adjusted 
for age and sex
HR (95% CI) also adjusted 
for other demographic 
factors†
HR (95% CI) also adjusted 
for comorbidities‡
Hospitalisation
COPD 1555 (0·8%)/193 520 5·09 (4·83–5·36) 1·85 (1·75–1·95) 1·79 (1·70–1·90) 1·54 (1·45–1·63)
Asthma 2266 (0·2%)/1 090 028 1·22 (1·17–1·28) 1·39 (1·33–1·46) 1·32 (1·26–1·38) 1·18 (1·13–1·24)
Active asthma 1720 (0·3%)/535 126 1·95 (1·85– 2·05) 1·56 (1·48–1·64) 1·43 (1·35–1·50) 1·26 (1·20–1·33)
Severe asthma 1369 (0·4%)/385 702 2·14 (2·02–2·26) 1·65 (1·56–1·75) 1·47 (1·39–1·55) 1·29 (1·22–1·37)
Bronchiectasis 319 (0·8%)/41 271 4·53 (4·06–5·07) 1·70 (1·52–1·90) 1·67 (1·49–1·87) 1·34 (1·20–1·50)
Cystic fibrosis 5 (0·2%)/2081 1·37 (0·57–3·30) 1·62 (0·67–3·89) 1·78 (0·74–4·28) 1·55 (0·65–3·73)
Sarcoidosis 84 (0·5%)/17 624 2·74 (2·21–3·39) 1·74 (1·40–2·15) 1·53 (1·23–1·90) 1·36 (1·10–1·68)
Extrinsic allergic alveolitis 16 (0·7%)/2331 3·97 (2·43–6·48) 1·75 (1·07–2·85) 1·86 (1·14–3·03) 1·35 (0·82–2·21)
Idiopathic pulmonary 
fibrosis
110 (1·5%)/7454 8·80 (7·29–10·62) 2·40 (1·99–2·89) 2·28 (1·89–2·75) 1·59 (1·30–1·95)
Other interstitial lung 
diseases
73 (1·3%)/5677 7·57 (6·02–9·53) 2·54 (2·02–3·20) 2·43 (1·93–3·05) 1·66 (1·30–2·12)
Lung cancer 139 (1·3%)/10 792 7·92 (6·70–9·36) 2·73 (2·31–3·23) 2·63 (2·22–3·11) 2·24 (1·89–2·65)
ICU admission§
COPD 59 (<0·1%)/193 520 1·68 (1·29–2·18) 0·85 (0·65–1·11) 0·92 (0·70–1·20) 0·89 (0·68–1·17)
Asthma 213 (<0·1%)/1 090 028 1·05 (0·91–1·22) 1·18 (1·02–1·36) 1·09 (0·95–1·27) 1·08 (0·93–1·25)
Active asthma 165 (<0·1%)/535 126 1·73 (1·47–2·03) 1·62 (1·37–1·90) 1·36 (1·16–1·61) 1·34 (1·14–1·58)
Severe asthma 124 (<0·1%)/385 702 1·79 (1·49–2·15) 1·64 (1·37–1·98) 1·33 (1·10–1·60) 1·30 (1·08–1·58)
Bronchiectasis 18 (<0·1%)/41 271 2·37 (1·49–3·78) 1·36 (0·85–2·17) 1·46 (0·91–2·33) 1·47 (0·91–2·36)
Sarcoidosis 10 (0·1%)/17 624 3·06 (1·64–5·70) 2·22 (1·19–4·14) 1·65 (0·89–3·08) 1·51 (0·81–2·81)
Idiopathic pulmonary 
fibrosis
6 (0·1%)/7454 4·48 (2·01–9·99) 1·87 (0·84–4·18) 1·88 (0·84–4·19) 1·97 (0·85–4·55)
Death¶
COPD 811 (0·4%)/193 520 6·66 (6·19–7·18) 1·82 (1·69–1·96) 1·64 (1·51–1·77) 1·54 (1·42–1·67)
Asthma 762 (0·1%)/1 090 028 0·96 (0·89–1·04) 1·19 (1·1–1·28) 1·12 (1·04–1·21) 0·99 (0·91–1·07)
Active asthma 602 (0·1%)/535 126 1·62 (1·49–1·77) 1·28 (1·18–1·39) 1·18 (1·09–1·29) 1·05 (0·96–1·15)
Severe asthma 476 (0·1%)/385 702 1·78 (1·62–1·95) 1·35 (1·23–1·48) 1·21 (1·11–1·34) 1·08 (0·98–1·19)
Bronchiectasis 138 (0·3%)/41 271 4·77 (4·03–5·65) 1·35 (1·14–1·60) 1·29 (1·09–1·52) 1·12 (0·94–1·33)
Sarcoidosis 32 (0·2%)/17 624 2·53 (1·79–3·58) 1·63 (1·15–2·31) 1·58 (1·11–2·23) 1·41 (0·99–1·99)
Extrinsic allergic alveolitis 8 (0·3%)/2331 4·82 (2·41–9·65) 1·75 (0·87–3·50) 2·02 (1·01–4·03) 1·56 (0·78–3·13)
Idiopathic pulmonary 
fibrosis
62 (0·8%)/7454 12·09(9·42–15·53) 2·14 (1·66–2·74) 2·04 (1·58–2·62) 1·47 (1·12–1·92)
Other interstitial lung 
diseases
45 (0·8%)/5677 11·37 (8·48–15·25) 2·7 (2·01–3·62) 2·71 (2·02–3·63) 2·05 (1·49–2·81)
Lung cancer 60 (0·6%)/10 792 8·33 (6·46–10·74) 2·18 (1·69–2·81) 1·95 (1·51–2·51) 1·77 (1·37–2·29)
Individuals could have more than one respiratory disease. COPD=chronic obstructive pulmonary disease. HR=hazard ratio. ICU=intensive care unit. *Adjusted for all other 
respiratory diseases. †Also adjusted for ethnicity, socioeconomic status, region of England, body-mass index (categorical variable), and smoking status (with current intensity 
of smoking as categorical variables). ‡Also adjusted for non-smoking-related illness (hypertension, type 1 diabetes, chronic liver disease, chronic neurological disease) and 
smoking-related illness (coronary heart disease, stroke, atrial fibrillation, type 2 diabetes, chronic kidney disease). §Data for people with cystic fibrosis, sarcoidosis, extrinsic 
allergic alveolitis, idiopathic pulmonary fibrosis, other interstitial lung disease, and lung cancer not presented because fewer than five people had the outcome. ¶Data for 
people with cystic fibrosis not presented because there were no deaths in this group.
Table 1: Risk of severe COVID-19 outcomes for people with underlying respiratory disease
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All patients 20 years or older who were registered with 
one of the 1205 general practices on Jan 24, 2020, were 
included in the cohort. Patients were censored following 
the date of death, occurrence of the relevant outcome of 
interest (either hospital admission, ICU admission, or 
death), or study end date (April 30, 2020), whichever 
occurred first. This population cohort study was approved 
by the QResearch Science Committee, which has delegated 
power from the NHS ethics committee to approve studies 
using QResearch.
Procedures 
We examined the risk of severe COVID-19 in relation to 
COPD, asthma, bronchiectasis, cystic fibrosis, sarcoidosis, 
extrinsic allergic alveolitis (also known as hyper sensitivity 
pneumonitis), idiopathic pulmonary fibrosis, other 
interstitial lung disease, and lung cancer compared with 
people without these diseases. In a post-hoc analysis, risk 
of severe COVID-19 was assessed in patients with active 
asthma (defined as having at least one prescription for 
asthma medication) and severe asthma (defined as being 
prescribed at least three different classes of medication for 
asthma in the year before cohort entry). These exposures 
were derived from the primary care record only and 
recorded any time since registration in the practice. 
General practitioners will typically diagnose COPD and 
asthma, and will probably record all serious diagnoses 
made in secondary or tertiary care, such as interstitial lung 
disease. The observed prevalence matched that expected 
from epidemiological surveys.12 We coded a person as 
exposed to ICS if they were prescribed ICS at least twice 
within 150 days of the study start date.
We assessed the potential confounders by creating 
directed acyclic graphs. For the associations between 
respiratory disease and COVID-19 severity, we identified 
three causal paths: a direct path and two through 
treatments, which for these analyses we classified as ICS 
and other treatments for airways disease (appendix p 1). 
The potential confounding paths were blocked by 
controlling for smoking, body-mass index (BMI), and 
demographic factors (age as a continuous variable, sex, 
ethnic group, socioeconomic status, and region of 
England). Because adjusting for smoking status and 
demographic factors might not completely block 
confounding, we adjusted for smoking-related and 
non-smoking-related morbidity, including all other 
respiratory diseases.
We hypothesised only one causal path between ICS use 
and severe COVID-19 in the directed acyclic graphs 
(appendix p 1): respiratory disease. Thus, controlling for 
this respiratory disease will block all other paths to the 
outcome. However, as factors related to severity of disease 
were not recorded, we also adjusted for demographic 
factors, smoking, BMI, other comorbid conditions, and 
number of airways medications (an indirect marker). 
Number of treatments was defined as the number of 
classes of respiratory drugs prescribed (short-acting 
β-agonists, long-acting β-agonists, long-acting musc arinic 
antagonist, leukotriene receptor antagonists, and theo-
phyllines); use of respiratory drugs was determined by two 
or more prescriptions received within 150 days before 
cohort entry and classified as three or more versus one 
or two. All covariates were obtained from general practice 
records before cohort entry.
Outcomes 
The outcomes were hospital admission, ICU admission, 
and death due to COVID-19. Hospital admission was 
defined as a positive test for SARS-CoV-2 and appearing 
in the Hospital Episode Statistics dataset as an in-patient 
within 30 days of that test or having an International 
Classification of Diseases (ICD)-10 code U07.1 for 
confirmed COVID-19 or U07.2 for suspected COVID-19. 
Admission to ICU was defined as admission to an ICU 
with severe COVID-19 (ICD-10 code U07.1 or U07.2) in 
ICNARC records. Death from COVID-19 was defined as 
having confirmed or suspected COVID-19 (ICD-10 codes 
U07.1 and U07.2) on the death certificate, including 
deaths in and out of hospital.
Residents of care homes are almost all extremely frail, 
which is the strongest risk factor for adverse outcomes 
from SARS-CoV-2 infection.13 Although respiratory 
disease might cause frailty and the need for care, the 
experience of this group is not representative of most 
people with underlying respiratory disease. In a post-hoc 
analysis, we analysed death from COVID-19 excluding all 
care home residents.
We examined the effect of the national lockdown and 
shielding introduced in England on March 23, 2020. 
Number of patients 
who died (n [%]/N)
HR (95% CI) *
COPD 627 (0·3%)/189 533 1·55 (1·41–1·70)
Asthma 617 (0·1%)/1 084 522 1·05 (0·96–1·15)
Active asthma 502 (0·1%)/531 517 1·13 (1·03–1·25)
Severe asthma 400 (0·1%)/382 987 1·15 (1·04–1·28)
Bronchiectasis 112 (0·3%)/40 633 1·20 (0·99–1·45)
Sarcoidosis 25 (0·1%)/17 507 1·37 (0·92–2·03)
Extrinsic allergic alveolitis 6 (0·3%)/2309 1·40 (0·63–3·15)
Idiopathic pulmonary fibrosis 50 (0·7%)/7252 1·54 (1·14–2·08)
Other interstitial lung diseases 41 (0·7%)/5589 2·37 (1·70–3·31)
Lung cancer 53 (0·5%)/10 535 2·07 (1·57–2·72)
People with active asthma had at least one prescription for asthma medication. 
People with severe asthma were prescribed at least three different classes of 
medication for asthma in the year before cohort entry. COPD=chronic obstructive 
pulmonary disease. HR=hazard ratio. *Adjusted for demographic factors (age, 
gender, ethnicity, socioeconomic status, region of England), body-mass index 
(categorical variable), smoking status, non-smoking-related illness 
(hypertension, type 1 diabetes, chronic liver disease, and chronic neurological 
disease), smoking-related illness (coronary heart disease, stroke, atrial fibrillation, 
type 2 diabetes, and chronic kidney disease), and all other respiratory diseases. 
†Data for people with cystic fibrosis not presented as nobody with cystic fibrosis 
died.
Table 2: The association between respiratory disease and risk of 
COVID-19 death excluding care home residents†
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Lockdown was a legal requirement for everyone except 
essential workers to stay at home, with dispensation for 
essential shopping and exercising. Shielding asked people 
with diseases or medications that were assumed to convey 
extreme risk of severe COVID-19 to stay at home at all 
times, with support provided to achieve this. Shielding 
also required practisers to minimise any social contact, 
even with members of the same household.
We assessed whether there was evidence that the 
associations between two common respiratory diseases, 
COPD and asthma, and severe COVID-19 were modified 
by age, sex, ethnicity, and smoking status.
We calculated representative absolute death rates from 
COVID-19 for people of various ages with and without 
respiratory disease, presenting the difference. To put the 
mortality rates into context, we compared excess deaths in 
people with respiratory diseases with so-called normal risk.
Statistical analysis 
We used Cox’s proportional hazards models to estimate 
the mutually adjusted HRs for the associations between 
each respiratory disease and each of the severe COVID-19 
outcomes and to estimate the mutually adjusted HRs 
between ICS use and severe COVID-19, with Stata 
(version 16.0). HRs were adjusted for patient age, sex, 
demographic factors, and comorbidities in all analyses. 
When adjustment variables had missing values, we 
included these participants in a missing category.
In the post-hoc analyses, we excluded people living in 
care homes and reran the analysis to examine the risk of 
death from COVID-19. To assess the effects of shielding, 
we reassessed hospitalisation, ICU admissions, and 
deaths, censoring outcomes on March 31, 2020, for the 
preshielding period, and from April 1–30, 2020, for the 
post-shielding period. To assess the effect of age, sex, 
ethnicity, and smoking status on the association between 
COPD and asthma and COVID-19, we added appropriate 
multiplicative interaction terms to the fully adjusted 
model described.
In the assessment of absolute death rates, Spiegelhalter 
defined normal risk as the risk of death from any cause that 
a person would face in the same time period,14 which was 
calculated with data from the Office for National Statistics.15 
For asthma and COPD, we present the risks assuming no 
interaction with age and then assuming age-specific risks.
Role of the funding source 
The study was funded by the National Institute for 
Health Research Oxford Biomedical Research Centre and 
the Wellcome Trust. The funders had no role in study 
design; data collection, analysis, and interpretation; 
writing of the Article; and the decision to submit it for 
publication.
Results 
Between Jan 24 and April 30, 2020, 8 256 161 adults were 
included in the cohort. The most common respiratory 
diseases were asthma (1 090 028 [13·2%] individuals), 
COPD (193 520 [2·3%] individuals), and bronchiectasis 
(41 271 [0·5%]; appendix p 2; table 1). During follow up, 
14 479 (0·2%) of  8 256 161 adults were admitted to hospital 
with COVID-19, 1542 (<0·1%) were admitted to ICU, and 
5956 (0·1%) died of COVID-19. In the whole population, 
1 271 108 (15·4%) had any respiratory disease. People with 
underlying respiratory disease gave rise to 3696 (25·5%) of 
14 479 hospital admissions, 275 (17·8%) of 1542 ICU 
admissions, and 1485 (24·9%) of 5956 deaths 
(appendix pp 2–7; tables 1 and 2).





COPD 1·54 (1·45–1·63) 1·54 (1·45–1·64) 1·53 (1·45–1·63)
Asthma 1·18 (1·13–1·24) 1·20 (1·14–1·26) 1·17 (1·11–1·28)
Active asthma 1·26 (1·20–1·33) 1·28 (1·21–1·35) 1·25 (1·20–1·33)
Severe asthma 1·29 (1·22–1·37) 1·30 (1·22–1·38) 1·28 (1·20–1·39)
Bronchiectasis 1·34 (1·20–1·50) 1·36 (1·21–1·53) 1·33 (1·19–1·49)
Cystic fibrosis 1·55 (0·65–3·73) 1·65 (0·69–3·97) 1·55 (0·62–3·81)
Sarcoidosis 1·36 (1·10–1·68) 1·37 (1·10–1·70) 1·25 (0·99–1·58)
Extrinsic allergic alveolitis 1·35 (0·82–2·21) 1·36 (0·83–2·21) 1·22 (0·70–2·10)
Idiopathic pulmonary fibrosis 1·59 (1·30–1·95) 1·60 (1·31–1·95) 1·54 (1·24–1·91)
Other interstitial lung diseases 1·66 (1·30–2·12) 1·67 (1·30–2·13) 1·62 (1·25–2·11)
Lung cancer 2·24 (1·89–2·65) 2·31 (1·94–2·75) 2·23 (1·88–2·64)
ICU admission†
COPD 0·89 (0·68–1·17) 0·89 (0·68–1·17) 0·80 (0·59–1·09)
Asthma 1·08 (0·93–1·25) 1·10 (0·94–1·28) 1·07 (0·91–1·27)
Active asthma 1·34 (1·14–1·58) 1·37 (1·14–1·63) 1·32 (1·14–1·59)
Severe asthma 1·30 (1·08–1·58) 1·36 (1·06–1·59) 1·29 (1·08–1·60)
Bronchiectasis 1·47 (0·91–2·36) 1·49 (0·91–2·35) 1·33 (0·78–2·27)
Sarcoidosis 1·51 (0·81–2·81) 1·53 (0·82–2·81) 1·19 (0·57–2·51)
Idiopathic pulmonary fibrosis 1·97 (0·85–4·55) 2·35 (1·01–5·47) 1·96 (0·85–4·54)
Death‡
COPD 1·54 (1·42–1·67) 1·55 (1·31–1·68) 1·49 (1·36–1·63)
Asthma 0·99 (0·91–1·07) 0·98 (0·91–1·07) 1·01 (0·93–1·10)
Active asthma 1·05 (0·96–1·15) 1·04 (0·97–1·15) 1·06 (0·95–1·17)
Severe asthma 1·08 (0·98–1·19) 1·07 (0·98–1·19) 1·09 (0·97–1·21)
Bronchiectasis 1·12 (0·94–1·33) 1·13 (0·98–1·42) 1·11 (0·93–1·34)
Sarcoidosis 1·41 (0·99–1·99) 1·42 (1·00–2·00) 1·22 (0·80–1·86)
Extrinsic allergic alveolitis 1·56 (0·78–3·13) 1·57 (0·78–3·14) 1·42 (0·36–2·56)
Idiopathic pulmonary fibrosis 1·47 (1·12–1·92) 1·48 (1·11–1·92) 1·30 (0·94–1·77)
Other interstitial lung 
diseases
2·05 (1·49–2·81) 2·06 (1·50–2·82) 2·04 (1·48–2·95)
Lung cancer 1·77 (1·37–2·29) 1·89 (1·43–2·48) 1·76 (1·36–2·27)
Data are hazard ratio (95% CI). People with active asthma had at least one prescription for asthma medication. People 
with severe asthma were prescribed at least three different classes of medication for asthma in the year before cohort 
entry. COPD=chronic obstructive pulmonary disease. ICU=intensive care unit. *Adjusted for demographic factors (age, 
gender, ethnicity, socioeconomic status, and region of England), body-mass index (categorical variable), smoking 
status, non-smoking-related illness (hypertension, type 1 diabetes, chronic liver disease, and chronic neurological 
disease), smoking-related illness (coronary heart disease, stroke, atrial fibrillation, type 2 diabetes, and chronic kidney 
disease), and all other respiratory diseases. †Data for people with cystic fibrosis, sarcoidosis, extrinsic allergic alveolitis, 
idiopathic pulmonary fibrosis, other interstitial lung disease, and lung cancer not presented because fewer than 
five people had the outcome. ‡Data for people with cystic fibrosis not presented as there were no deaths in this group.
Table 3: Modification of the association between respiratory disease and severe COVID-19 by the 
introduction of lockdown and shielding
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Figure 1:Association between 
COPD and severe COVID-19 
on hospitalisation (A), ICU 
admission (B), and death (C)
COPD=chronic obstructive 
pulmonary disease. HR=hazard 
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Figure 2: Association between 
asthma and severe COVID-19 
on hospitalisation (A), ICU 
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Figure 3: Association 
between active asthma and 
severe COVID-19 on 
hospitalisation (A), ICU 
admission (B), and death (C)
People with active asthma had 
at least one prescription for 
asthma medication in the year 
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Figure 4: Association 
between severe asthma and 
severe COVID-19 on 
hospitalisation (A), ICU 
admission (B), and death (C)
People with severe asthma 
were prescribed at 
least three different classes of 
medication for asthma in the 
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Adjusted for age and sex only, all respiratory diseases 
were associated with increased risk of hospitalisation with 
COVID-19 compared with those without respiratory 
diseases (table 1; appendix p 2). People with asthma had 
the lowest risk, with a 39% increase in risk compared with 
people without asthma, whereas people with lung cancer 
were more than twice as likely to be hospitalised with 
COVID-19. After adjustment for other demographic 
factors, BMI, smoking status, and other comorbidities, 
these risks decreased; however, people with respiratory 
diseases were still at increased risk of hospitalisation (HR 
1·54 [95% CI 1·45–1·63] for COPD, 1·18 [1·13–1·24] for 
asthma, 1·29 [1·22–1·37] for severe asthma, 1·34 [1·20–
1·50] for bronchiectasis, 1·36 [1·10–1·68] for sarcoidosis, 
1·35 [0·82–2·21] for extrinsic allergic alveolitis, 1·59 
[1·30–1·95] for idiopathic pulmonary fibrosis, 
1·66 [1·30–2·12] for other interstitial lung disease, and 
2·24 [1·89–2·65] for lung cancer). The HRs indicated risk 
of hospitalisation for most respiratory diseases was 
increased by between 30% and 50%, with an 18% increase 
in risk for all people with asthma. In people with active 
asthma, there was a 26% increased risk, and for severe 
asthma, a 29% increased risk. People with lung cancer 
were at twice the risk of admission to hospital compared 
with people without lung cancer.
People with interstitial lung diseases and cystic fibrosis 
were very rarely admitted to ICU and so the HRs were not 
calculated. After full adjustment, there was no evidence 
that people with asthma, COPD, or bronchiectasis were 
more likely to be admitted to ICU than the people without 
these conditions. The HR for asthma was 1·08 (95% CI 
0·93–1·25); however, people with active asthma (34%) 
and severe asthma (30%; HR 1·30 [1·08–1·58]) were at 
higher risk of ICU admission (table 1).
Having COPD was associated with a 54% (HR 1·54 
[95% CI 1·42–1·67]) increase in the risk of death due to 
COVID-19 in the fully adjusted model, whereas there was 
no evidence that people with asthma were at an increased 
risk of death (0·99 [0·91–1·07]), even for people with active 
asthma (1·05 [0·96–1·15]) and severe asthma (1·08 
[0·98–1·19]). Most interstitial lung diseases were associated 
with a 50% increased risk of death, but the estimates were 
imprecise (1·41 [0·99–1·99] for those with sarcoidosis, 
1·56 [0·78–3·13] for those with extrinsic allergic alveolitis, 
1·47 [1·12–1·92] for those with idiopathic pulmonary 
fibrosis, and 2·05 [1·49–2·81] for those with other 
interstitial lung disease). The risk of death in people with 
lung cancer (1·77 [1·37–2·29]) was 77% higher than in the 
general population (table 1). HR for death in individuals 
with bronchiectasis was 1·12 [0·94–1·33]. No one with cystic 
fibrosis died because of  COVID-19.
1565 (3·1%) of 50 769 residents in care homes died due 
to COVID-19, which accounted for 26·3% of all deaths 
from COVID-19. Therefore, in a post-hoc analysis, we 
reanalysed the death outcome, excluding individuals 
living in care homes. Because care home residents gave 
rise to 1264 (8·7%) of 14479 hospitalisations and 12 (0·8%) 
of 1542 ICU admissions, we did not reanalyse these 
outcomes. This sensitivity analysis showed that the HRs 
for COVID-19-related death associated with respiratory 
disease were generally lower in the population outside of 
care homes than in the whole population (table 2).
6857 hospital admissions, 655 ICU admissions, and 
905 deaths occurred before shielding guidance could have 
modified risk for people with underlying respiratory 
disease. After the implementation of shielding guidance, 
7622 hospital admissions, 887 ICU admissions, and 
Assuming hazard ratio constant with age Assuming hazard ratio differs by age
Mortality from COVID-19 
per 100 000 population*
Percentage of 
normal risk†
Mortality from COVID-19 




40–59 years 7 17% 48 117%
60–79 years 56 12% 130 28%
≥80 years 389 38% 202 20%
Asthma
20–39 years 0 0% 1 5%
40–59 years 0 0% 4 10%
60–79 years 0 0% 9 2%
≥80 years 0 –1% –108‡ –11%‡
Active asthma
20–39 years 0 0% 3 15%
40–59 years 1 2% 12 29%
60–79 years 5 1% 24 5%
≥80 years 36 4% –115‡ –11%‡
Severe asthma
20–39 years 0 0% 2 10%
40–59 years 1 2% 12 29%
60–79 years 8 2% 32 7%
≥80 years 58 6% –115‡ –11%‡
Bronchiectasis
20–39 years 0 0% ·· ··
40–59 years 2 5% ·· ··
60–79 years 12 3% ·· ··
≥80 years 86 8% ·· ··
Sarcoidosis
20–39 years 1 5% ·· ··
40–59 years 5 12% ·· ··
60–79 years 42 9% ·· ··
≥80 years 295 29% ·· ··
Extrinsic allergic alveolitis
20–39 years 1 5% ·· ··
40–59 years 7 17% ·· ··
60–79 years 58 13% ·· ··
≥80 years 403 40% ·· ··
Idiopathic pulmonary fibrosis
20–39 years 1 5% ·· ··
40–59 years 6 15% ·· ··
60–79 years 49 11% ·· ··
≥80 years 338 33% ·· ··
(Table 4 continues on next page)
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5051 deaths occurred. The association between previous 
respiratory disease and severe COVID-19 was generally 
similar before and after shielding was introduced (table 3).
There was also a consistent pattern of effect 
modification by sex for both asthma and COPD 
(figure 1, 2). Women with these diseases were at 
statistically significantly higher relative hazard of 
hospitalisation, ICU admission, and death compared 
with men for all but one analysis.
The risks of hospitalisation, ICU admission, and death 
due to COVID-19 for people with asthma appeared 
similar for each ethnic group (figure 2). For COPD, there 
was evidence that the risk varied by ethnicity. The risks 
for hospitalisation and death associated with COPD were 
higher in white individuals than all other ethnic groups, 
except the group without recorded ethnicity (figure 1). 
There was no evidence of an effect modification for ICU 
admission.
The HR associated with asthma was significantly 
modified by age (figure 2). For people younger than 
40 years, asthma was associated with a 59% increased 
risk of hospitalisation, and a more than doubling in the 
risk of ICU admission and death, but the HRs for 
asthma in individuals 40 years or older were lower 
(figure 2). The same pattern was evident in people with 
COPD (figure 1), active asthma (figure 3), and severe 
asthma (figure 4). To investigate this pattern, we looked 
for risk factor differences between people admitted to 
hospital with asthma or COPD and people who were not 
that varied by age. In people younger than 40 years, the 
mean BMI of people admitted to hospital with 
COVID-19 was 29·5 kg/m², of those admitted to ICU 
was 33·0 kg/m², and for people who died was 
30·9 kg/m², compared with 25·9 kg/m² in people 
younger than 40 years without severe COVID-19. These 
BMI differences between people with and without 
severe COVID-19 got progressively smaller with each 
age group above that, with no difference in BMI 
apparent in people older than 80 years with and without 
severe COVID-19, mirroring the age-specific estimates 
of risk of severe COVID-19.
There was little evidence that smoking modified the 
risks associated with asthma and COPD (figures 1, 2). 
People who smoked and had COPD were at higher risk 
of admission to hospital with COVID-19 than people 
who were not currently smoking but had COPD 
(figure 1). However, there was no evidence of similar 
effect modification for ICU admission or death due to 
COVID-19 (figure 1). There was no evidence that 
smoking was associated with modified risk in people 
with asthma (figure 2).
The absolute risk of death from COVID-19 for people 
with respiratory disease compared with those without 
respiratory disease was low in absolute terms (table 4). In 
particular, risk of death was lower than the normal risk of 
death in all groups, except for people with COPD aged 
40–59 years. However, for most other diseases and age 
groups, the excess risk of death from COVID-19 
experienced by people with respiratory disease was far 
lower than the risk of death between January and 
April, 2020, for the general population.
450 784 (5·5%) people in the whole population were 
using ICS regularly compared with 89 605 (46·3%) 
of 193 520 people with COPD; 368 496 (33·8%) of 
1 090 028 people with asthma; 368 496 (68·9%) 
of 535 126 people with active asthma; and 316 719 (82·1%) 
of 385 702 people with severe asthma. Of the 450 784 people 
using ICS regularly, 342 982 (76·1%) were using at least 
three airways medications. Overall, there was evidence that 
use of ICS was associated with a modest risk of severe 
COVID-19 independently of under lying respiratory disease 
(HR 1·13 [1·03–1·23] for hospitalisation, 1·63 [1·18–2·24] 
for ICU admission, and 1·15 [1·01–1·31] for death; table 5); 
however, these risks were reduced when other risk factors 
were taken into account.
Discussion 
People with pre-existing respiratory disease had a 
modestly increased risk of severe COVID-19 in this 
representative community cohort. People with asthma 
had an 18% increased risk of hospital admission with 
COVID-19, but there was no evidence that asthma 
was associated with an increased risk of death. Even in 
people with asthma who were prescribed three or more 
airways medications, the risk of death was modestly 
raised at worst compared with people without 
respiratory conditions. In the whole population, COPD 
was associated with a 54% increase in the risk of 
Assuming hazard ratio constant with age Assuming hazard ratio differs by age
Mortality from COVID-19 
per 100 000 population*
Percentage of 
normal risk†
Mortality from COVID-19 
per 100 000 population*
Percentage of 
normal risk†
(Continued from previous page)
Other interstitial lung diseases
20–39 years 1 5% ·· ··
40–59 years 14 34% ·· ··
60–79 years 109 24% ·· ··
≥80 years 756 74% ·· ··
Lung cancer
20–39 years 1 5% ·· ··
40–59 years 10 24% ·· ··
60–79 years 80 17% ·· ··
≥80 years 555 55% ·· ··
People with active asthma had at least one prescription for asthma medication. People with severe asthma were 
prescribed at least three different classes of medication for asthma in the year before cohort entry. 
COPD=chronic obstructive pulmonary disease. *Difference in absolute mortality between people without compared 
with those with respiratory disease. †Percentage of normal risk is the COVID-19 deaths divided by absolute risk of 
death from any cause over 4 months, where all-cause mortality is based on data from 2017–2019; the normal 
mortality rate for a 4-month period of people aged 20–39 is 19·4 per 100 000, for people aged 40–59 is 40·9 per 
100 000, for people aged 60–79 is 460·1 per 100 000, and for people aged 80 years and older is 1015·1 per 100 000. 
‡Numbers are negative because the risk of COVID-19 mortality in people older than 80 years with asthma or COPD is 
lower than in people without such diseases. 
Table 4: Absolute difference in risk of death from COVID-19 in people with respiratory disease compared 
with people without respiratory disease and percentage of normal risk
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hospitalisation or death. The risks in people with 
bronchiectasis were modestly above one, although they 
were imprecisely estimated for death. Cystic fibrosis was 
too uncommon to estimate risks with precision, with 
only five of the 2081 patients in our cohort having a 
severe outcome, and no one with cystic fibrosis died 
from COVID-19. Interstitial lung disease was associated 
with an increased risk of severe COVID-19, while lung 
cancer was associated with a near doubling of severe 
COVID-19. People using ICS were at modestly increased 
risk of severe COVID-19 adjusted for respiratory disease 
and other comorbidities.
In this large representative sample of the general 
population, there was previous recording of exposures and 
potential confounders. As such, this study is likely to have 
more complete capture of exposures and confounders 
than studies of patients who were hospitalised, which 
might be affected by patients’ poor recall or the urgency of 
caring for people with severe COVID-19. Moreover, 
hospital-based cohorts can distort the strength of 
association between an exposure and severe COVID-19 
through collider bias,16 a factor that did not apply here. 
However, our exposures were restricted to the presence or 
absence of respiratory disease and did not record its 
severity. ISARIC reported that interstitial lung disease with 
greater restrictive lung function was associated with worse 
outcomes.5 Our estimates of association are likely to 
overestimate the risks in people with mild disease and 
underestimate them in people with more severe disease. 
General practice records capture all prescriptions issued by 
general practitioners. Our classification of people as 
regular ICS users if they received at least two prescriptions 
in the 150 days before cohort entry might have classified 
some regular users as non-users, and some people 
fulfilling that definition might not have been using steroids 
at the relevant time of exposure. Exposure misassignment 
is unlikely to relate to an acute outcome like severe 
COVID-19 and thus is likely to move estimated associations 
towards the null. Additionally, our use of ICU care to 
indicate severe disease, in common with many studies, is a 
limitation. Most people who worsen with COVID-19 will 
not be admitted to ICU because their underlying health 
state suggests little likelihood of benefit. As such, low rates 
of ICU admission for people with COPD, interstitial lung 
disease, and lung cancer probably reflect the selection 
process and not the severity of COVID-19. A final limitation 
is our definition of severe COVID-19. So-called long 
COVID is an important outcome of COVID-19, but our 
dataset is unable to capture risk of this condition.17 People 
with asthma might be at increased risk of longer duration 
of symptoms from COVID-19.18
Because of an expectation of increased risk, it is 
possible that people with underlying respiratory disease 
could have more rigorously instituted behavioural 
measures to reduce their risk of infection from 
SARS-CoV-2 than people without respiratory conditions. 
This might mean we have underestimated the true risk 
of severe COVID-19. The introduction of shielding meant 
that people with interstitial lung disease and cystic 
fibrosis probably had less social contact than people 
without these diseases, and the risks associated with 
these conditions might have been expected to fall, but we 
saw only a small amount of evidence supporting this. 
Our estimates of relative risk for people with underlying 
respiratory disease reflect a combination of the risk 
conferred by that disease and the social distancing that 
people with respiratory disease might have instituted, 
which might have been more vigorous than that of the 
general population with or without shielding.
There are few data on the association between 
respiratory disease and COVID-19. A systematic review 
reported on 21 studies (n=12 976), all of which comprised 
cohorts of patients defined by admission to hospital with 
outcomes representing worsening illness, need for ICU 
care, and death.3 The odds ratio (OR) for severe COVID-19 
with any form of respiratory disease was 4·2 
(95% CI 2·9–6·0), with no differentiation between 
respiratory diseases. Selecting only people with COVID-19 
that is severe enough to warrant hospital admission 
means collider bias could have distorted these associations. 
The prevalence of people with respiratory disease in 
patients hospitalised with COVID-19 appears to be lower 
than the prevalence in the general population. It is 
possible that those admitted with respiratory disease were 
more frail than those without, creating the impression 
that respiratory disease confers greater risk than is actually 
the case.19 To our knowledge, ISARIC is the only study to 
have examined risks in people with interstitial lung 
disease.5 In patients admitted to hospital, people with 
interstitial lung disease matched for age, sex, and 
comorbidity had an HR of 1·60 (95% CI 1·17–2·18) for 
death. The risks were slightly higher in people with 
idiopathic pulmonary fibrosis (1·74 [1·16–2·60]) than in 
those with other forms of interstitial lung disease (1·50 
[1·02–2·21]).5 These estimates are slightly higher than the 
estimates we produced, but we adjusted for more 
potentially confounding variables and included all people 
Unadjusted HR 
(95% CI)




HR (95% CI)  
also adjusted for 
demographic 
factors†
HR (95% CI)  
also adjusted for 
smoking-related 
morbidity‡
Hospital admission 2·72 (2·60–2·85) 2·06 (1·94–2·19) 0·97 (0·89–1·05) 1·13 (1·03–1·23)
ICU admission 2·10 (1·78–2·46) 2·52 (2·03–3·13) 1·64 (1·20–2·23) 1·63 (1·18–2·24)
Death 2·63 (2·44–2·84) 2·04 (1·85–2·25) 0·94 (0·83–1·07) 1·15 (1·01–1·31)
People with active asthma had at least one prescription for asthma medication. People with severe asthma were 
prescribed at least three different classes of medication for asthma in the year before cohort entry. HR=hazard ratio. 
ICU=intensive care unit. *Adjusted for presence of chronic obstructive pulmonary disease, asthma, bronchiectasis, 
sarcoidosis, extrinsic allergic alveolitis, idiopathic pulmonary fibrosis, cystic fibrosis, other interstitial lung disease, and 
lung cancer. †Adjusted for sex, age, ethnicity, socioeconomic status, region of England, body-mass index, and smoking 
status as categorical variables, and number of airways medications (3 or more or fewer). ‡Adjusted for non-smoking-
related illness (hypertension, type 1 diabetes, chronic liver disease, and chronic neurological disease) and smoking-
related illness (coronary heart disease, stroke, atrial fibrillation, type 2 diabetes, and chronic kidney disease).
Table 5: Association between regular use of inhaled corticosteroids and severe COVID-19
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with interstitial lung disease in the population. The only 
representative population cohort we know to have reported 
on these associations is the OpenSAFELY study10 of 
17 million patients in England. It reported on risk of death 
for people with asthma who had not used oral steroids 
within the past 4 months (HR 0·99 [0·93–1·05]), those 
who had used oral steroids within the past 4 months (1·13 
[1·01–1·26]), and all other respiratory diseases (1·63 
[1·55–1·71]). Although we did not differentiate people 
with asthma by oral steroid use, the estimates for asthma 
are remarkably similar to those in our cohort. A US cohort 
matched people with asthma infected with SARS-CoV-2 to 
people without asthma with a SARS-CoV-2 infection.20 
They reported that the risk of hospitalisation was similar 
in the two groups, ICU admission non-significantly less 
likely in patients without asthma who had a SARS-CoV-2 
infection, and death markedly less likely in people with 
asthma and COVID-19. Our findings on airways disease 
have expanded the current literature considerably, 
showing that asthma is associated with a very small 
increase in risk. The absence  of a substantial association 
might seem surprising, given that respiratory viral 
infection is the main cause of exacerbations of asthma.21 
However, the finding is compatible with data from a small 
cohort of patients with asthma who were hospitalised with 
COVID-19, which showed no evidence that COVID-19 
exacerbated asthma.21–23
No previous study has reported that the risk associated 
with asthma appears to be higher in women than in men. 
These results might reflect the fact that women have a 
higher prevalence of asthma and are at increased risk of 
severe asthma,22,23 whereas men (whether they have asthma 
or not) are at higher risk of severe COVID-19.24 It could be 
that women’s tendency towards severe asthma might 
explain why asthma appears to confer a slightly higher risk 
of severe COVID-19 for women than men, but any increase 
in risk for severe COVID-19 in women with asthma is low.
There is also a small amount of evidence on the 
association between ICS use and COVID-19. A systematic 
review reported that, in people admitted to hospital with 
severe COVID-19, use of ICS was associated with 
recovery, shorter duration of hospital stay, but no 
evidence of association with need for ICU care or death.25 
Since then, two studies in community cohorts have been 
reported. A Spanish cohort found that people using ICS 
were at lower risk of being hospitalised with COVID-19 
than people who did not use ICS, OR 0·58 (95% CI 
0·44–0·77).26 The OpenSAFELY cohort10 reported that in 
people with COPD, ICS use had a higher HR for death 
from COVID-19 of 1·39 (95% CI 1·10–1·76) than did 
long-acting β-agonists and long-acting muscarinic 
antagonist use.10 In people with asthma, ICS use had an 
HR of 1·14 (0·85–1·54) for low or medium dose, and 1·55 
(1·10–2·18) for high-dose ICS use, compared with short-
acting β-agonist only. We used a different approach for 
the analyses, but the OpenSAFELY10 estimates are similar 
to the ones we report for COVID-19 death associated with 
steroid use, adjusted for other respiratory illnesses, 
medication use, and other potential confounders. 
However, we also report estimates for the associations 
with hospitalisation and ICU care, which suggest similar 
relative hazards to those for death from COVID-19. 
Because ICS use will typically be higher in people with 
more severe disease, these data from community cohorts 
taken together suggest that ICS use does not influence 
the likelihood of severe COVID-19.
From the beginning of the pandemic, governments 
have warned people with respiratory disease that they are 
at higher risk of severe disease, and these warnings have 
been reflected by charities for people with respiratory 
disease.27,28 Our results do suggest that such diseases 
confer increased risk, but that the extent of this increase 
in risk, particularly for people with asthma, might be less 
than originally thought. COPD and interstitial lung 
disease appear to confer a 30–50% increased risk of 
severe COVID-19, while asthma confers a 10–30% 
increase compared with those without disease. By 
contrast, in the same models, being male was associated 
with a 46% increased risk of hospitalisation, a three-times 
higher risk of ICU admission, and an 86% increased risk 
of death compared with being female. People with 
respiratory disease feel particularly anxious about their 
disease predisposing them to severe COVID-19.29 
One study found that anxiety and depression increased 
during lockdown to a significantly greater extent in people 
with asthma than in those without.30 We know of no 
evidence that being a man generates the same degree of 
concern about risk of COVID-19 as that reported by 
people with asthma, when it presents an objectively 
higher risk. Our use of normal risks of mortality also put 
these risks in context. The risk of death from COVID-19 
perhaps caused by underlying respiratory disease was far 
lower than the ordinary risk of death in the 4 months 
(January to April, 2020) that included the peak of the 
SARS-CoV-2 epidemic in England. Although this could 
be partly due to behavioural responses of people with 
respiratory disease, the noticeably higher risk in people 
with diabetes,31 also subject to the same warnings 
regarding their susceptibility to severe COVID-19, 
together with our analyses suggest that this is not the 
whole explanation.
The assumption that pre-existing respiratory disease 
would inevitably lead to an increased risk from COVID-19 
was reasonable at the start of the pandemic, but as data 
continue to emerge, these assumptions might need to be 
revisited, and advice to people with respiratory disease 
from governments and charities should perhaps be 
substantially more reassuring.
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